For instance, in breast cancer models, PLGA nanoparticles co-encapsulating paclitaxel and anti-CTLA-4 antibodies demonstrated a 50% greater tumor regression rate than either agent alone, indicating a powerful synergy between cytotoxic and immunomodulatory mechanisms (Table 1) [42]. The gene discussed is CTLA4; the disease is neoplasm.